Ardelean Melania, Şirli Roxana, Sporea Ioan, Bota Simona, Martie Alina, Popescu Alina, Dănila Mirela, Timar Bogdan, Buzas Roxana, Lighezan Daniel
Department of Gastroenterology and Hepatology,"Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Department of Informatics and Biostatistics, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Med Ultrason. 2014 Dec;16(4):325-31.
The
of this study was to summarize the spectrum of pancreatic pathology assessed by contrast enhanced ultrasound (CEUS) in a single Gastroenterology Center and to emphasize its accuracy in assessing two of the most important pancreatic lesions: solid tumors and necrotic lesions in acute pancreatitis.
Our retrospective study included 197 patients with pancreatic lesions (de novo pancreatic masses; acute, severe pancreatitis; other pathologies) evaluated by CEUS from October 2009 to May 2013, in which a reference method (contrast CT/MRI) was available.
A conclusive diagnosis was established according to the EFSUMB Guidelines in 87.8% of the 197 cases. In 87.3% cases there was a perfect concordance between CEUS and the reference method (contrast CT/MRI). 95 examinations were made for pancreatic solid masses: 41.1% (39) were hypoenhanced, 34.7% (33) were hyperenhanced, and 20% (19) were isoenhancing - chronic pancreatitis and autoimmune pancreatitis - while in 4.2% (4) cases CEUS was inconclusive. 60 examinations were made in severe acute pancreatitis and in 50% (30) cases pancreatic necrosis was diagnosed. 42 examinations were performed for other lesions: 64.2% (27) pancreatic pseudocysts, 11.9% (5) cystic tumors, 23.8% (10) other pathologies (abscesses, fibrosis, etc). CEUS accuracy for solid tumors was 92.9%. For necrotic lesions the accuracy was 97.4%.
CEUS has turned to be a good method for the characterization of different pancreatic pathologies and for evaluating acute pancreatitis. CEUS was conclusive in 90% cases and it should be considered as a first line imaging method in clinical practice.
本研究的目的是总结在单一胃肠病中心通过对比增强超声(CEUS)评估的胰腺病理谱,并强调其在评估两种最重要的胰腺病变中的准确性:实体瘤和急性胰腺炎中的坏死性病变。
我们的回顾性研究纳入了2009年10月至2013年5月期间通过CEUS评估的197例胰腺病变患者(原发性胰腺肿块;急性、重症胰腺炎;其他病理情况),其中有可供参考的方法(对比CT/MRI)。
根据欧洲超声医学与生物学联合会(EFSUMB)指南,在197例病例中的87.8%建立了确定性诊断。在87.3%的病例中,CEUS与参考方法(对比CT/MRI)完全一致。对胰腺实体肿块进行了95次检查:41.1%(39例)表现为低增强,34.7%(33例)表现为高增强,20%(19例)表现为等增强——慢性胰腺炎和自身免疫性胰腺炎——而在4.2%(4例)病例中CEUS结果不明确。对重症急性胰腺炎进行了60次检查,其中50%(30例)诊断为胰腺坏死。对其他病变进行了42次检查:64.2%(27例)为胰腺假性囊肿,11.9%(5例)为囊性肿瘤,23.8%(10例)为其他病理情况(脓肿、纤维化等)。CEUS对实体瘤的准确性为92.9%。对坏死性病变的准确性为97.4%。
CEUS已成为一种用于鉴别不同胰腺病理情况和评估急性胰腺炎的良好方法。CEUS在90%的病例中具有确定性,在临床实践中应被视为一线成像方法。